Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine palmitoyltransferase–ORMDL sphingolipid biosynthesis regulator 3 complex (SPT–ORMDL3 complex)
- Target
- SPT–ORMDL3 complex
- Molecular classification
- Enzyme complex, Regulatory protein complex, Serine palmitoyltransferase-associated complex
01
Overview
The **serine palmitoyltransferase–ORMDL3 complex** (SPT–ORMDL3) is a regulatory protein complex in human cells that plays a pivotal role in the de novo synthesis of sphingolipids. Serine palmitoyltransferase (SPT) catalyzes the initial and rate-limiting step of sphingolipid biosynthesis by condensing serine and palmitoyl-CoA. ORMDL3 (ORMDL sphingolipid biosynthesis regulator 3) is a transmembrane ER protein that acts as a negative regulator of SPT, providing a ceramide-dependent feedback mechanism to maintain sphingolipid homeostasis. The SPT–ORMDL3 complex structure reveals interdependent subunits (SPTLC1, SPTLC2, SPTssa, and ORMDL3) assembled to enable tight enzyme regulation. Mutations or altered expression in ORMDL3 are associated with diseases such as asthma and ALS, reflecting the importance of sphingolipid homeostasis in diverse physiological and pathological contexts. No drugs currently target this complex directly, but it represents an attractive target for disorders of sphingolipid metabolism and inflammation.
- Other names
- SPT-ORMDL3 complexSPT–ORMDL3serine palmitoyltransferase–ORMDL3ORM1-like protein 3 complex
02
Mechanism of action
Inhibition or modulation of serine palmitoyltransferase (SPT) activity via allosteric mechanisms (notably by ceramide binding).
03
Biological functions
Sphingolipid biosynthesis regulationHomeostatic control of lipid metabolismCellular ceramide sensingRegulation of serine palmitoyltransferase activity
04
Disease associations
InflammationAsthmaPotential roles in childhood amyotrophic lateral sclerosis (ALS)Other sphingolipid-associated diseases
05
Safety considerations
Disrupting sphingolipid homeostasis can impact membrane integrity, neuronal homeostasis, and immune function.Mutations that disrupt SPT–ORMDL3 or ceramide sensing have been linked to neurodegeneration and inflammation.
06
Interacting drugs
None currently approved or in clinical use (the SPT–ORMDL3 complex is a potential future therapeutic target for small-molecule modulators but no drugs are listed affecting it directly).
07
Biomarkers
Altered ORMDL3 expression has been associated with asthma and inflammation risk.
Beyond the preview
Go deeper on Serine palmitoyltransferase–ORMDL sphingolipid biosynthesis regulator 3 complex (SPT–ORMDL3 complex).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serine palmitoyltransferase–ORMDL sphingolipid biosynthesis regulator 3 complex (SPT–ORMDL3 complex).